MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 30, 2006; DOI: 10.1124/mol.106.024513


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.024513v1
70/3/967    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Azam, L.
Right arrow Articles by McIntosh, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azam, L.
Right arrow Articles by McIntosh, J. M.


Received for publication March 16, 2006.
Revised May 30, 2006.
Accepted for publication May 30, 2006.

Characterization of Nicotinic Acetylcholine Receptors that Modulate Nicotine-evoked [3H]Norepinephrine Release from Mouse Hippocampal Synaptosomes

Layla Azam 1 J. Michael McIntosh 2*

1 University of Utah, Dept. of Biology 2 University of Utah, Departments of Biology and Psychiatry

* Address correspondence to: E-mail: mcintosh.mike{at}gmail.com

Abstract

Nicotine's modulation of hippocampal noradrenergic neurotransmission may contribute to its mnemonic properties, but the nAChR subtypes that modulate terminal release of norepinephrine are unknown. In the present study, we have used a number of subtype selective {alpha}-conotoxins in combination with nicotinic receptor subunit deficient mice to characterize nAChRs that modulate [3H]norepinephrine release from synaptosomes. The results indicate that at least 2 populations of nAChRs contribute to this release. These are a novel {alpha}6({alpha}4){beta}2{beta}3{beta}4 subtype and an {alpha}6({alpha}4){beta}2{beta}3 subtype. These are distinct from subtypes that modulate synaptosomal norepinephrine release in the rat hippocampus where an {alpha}6/{beta}2 and/or {alpha}6/{beta}4 ligand-binding interface is not present. Whereas {alpha}-conotoxin MII fully inhibits nicotine-evoked [3H]norepinephrine release in mouse, it is ineffective in blocking [3H]norepinephrine release in rat. Block of [3H]norepinephrine release by {alpha}-conotoxin BuIA, a toxin that kinetically distinguishes between {beta}2- and {beta}4-containing nAChRs, was partially reversible in mouse but irreversible in rat. This indicates that in contrast to rat, mouse nAChRs are made of both {beta}4 and non-{beta}4-containing populations. Results from {beta}2 and {beta}4 null mutant mice confirmed this conclusion, indicating the presence of the {beta}2 subunit in all nAChRs, and the presence of the {beta}4 subunit in a subpopulation of nAChRs. Additionally, both {alpha}4 and {beta}3 subunits are essential for formation of functional nAChRs on mouse noradrenergic terminals. Cytisine, a ligand formerly believed to be {beta}4-selective, was a highly efficacious agonist for {alpha}6{beta}2-containing nAChRs. The sum of these results suggests a possible novel nAChR subtype that modulates noradrenergic neurotransmission within the mouse hippocampus.


Key words: Adrenergic, Nicotinic cholinergic


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
L. Azam, D. Yoshikami, and J. M. McIntosh
Amino Acid Residues That Confer High Selectivity of the {alpha}6 Nicotinic Acetylcholine Receptor Subunit to {alpha}-Conotoxin MII[S4A,E11A,L15A]
J. Biol. Chem., April 25, 2008; 283(17): 11625 - 11632.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics